Table 1.
Calhex-231 on 10 µM Methoxamine pre-contracted tone |
IC50(µM) | Emax(%) | |||
+Endothelium | 2.01±0.61 | 96.2±2.3 | ||
−Endothelium | 2.00±0.27 | 94.4±3.1 | ||
+1 µM Calindol | 2.08±0.19 | 92±5.4 | ||
Calhex−231 on 60 mM KCl pre-contracted tone | ||||
+Endothelium | 1.93±0.40 | 98±1.5 | ||
−Endothelium | 2.02±0.23 | 97.1±2.2 | ||
NPS 2143 on - Endothelium pre-contracted vessels | ||||
Methoxamine | 2.97±0.34 | 99.1±3.2 | ||
KCl | 12.5±0.73a | 78.4±3.4a | ||
Calindol on 10 µM Methoxamine pre-contracted tone | ||||
+Endothelium | 2.06±0.24 | 96.48±1.4 | ||
−Endothelium | 2.66±0.30 | 94.4±2.8 | ||
+3 µM Calhex−231 | 2.58±0.35 | 97.2±1.1 | ||
Calindol on 60 mM KCl pre-contracted tone | ||||
+Endothelium | 3.26±0.24b | 82.2±2.3b | ||
−Endothelium | 3.41±0.32c | 83.4±1.6c |
P<0.05 vs. the effect of NPS 2143 on 10 µm Methoxamine pre-contracted tone.
P<0.05 vs. the effect of calindol on 10 µm Methoxamine precontracted tone in vessels with a functional endothelium (+endothelium).
P<0.01 vs. the effect of calindol on 10 µm Methoxamine precontracted tone in vessels lacking a functional endothelium (−endothelium).